We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Expert Warns of UDI Pitfalls, Advises Early Compliance

Expert Warns of UDI Pitfalls, Advises Early Compliance

August 22, 2014

Devicemakers could spare themselves time and money by checking with UDI-issuing agencies to see if they have a current account before applying for new licenses, a former FDA official says.

Jay Crowley, who was instrumental in writing the FDA’s unique device identification rule, said most manufacturers have already done business with at least one of the three standards bodies approved by the FDA to issue UDIs: GS1, HIBCC and ICCBBA. Companies with established accounts can avoid increased licensing fees by using that account, rather than opening a new one, he said.

Crowley, who now heads up the UDI practice at USDM Life Sciences in Santa Barbara, Calif., spoke at the recent FDAnews Medical Devices Quality Conference in Bethesda, Md.

Determining whether a prior account exists is just one of the many last-minute details manufacturers must consider when implementing UDIs, which will appear on Class III devices in September and roll out to all devices over the next seven years. Crowley stressed that it’s highly unlikely the FDA will extend the compliance timeline.

Manufacturers could benefit from complying with UDI ahead of their deadline, said Steve Niedelman, lead quality and regulatory systems consultant at King & Spalding. For instance, UDIs will make performing and analyzing recalls easier and could become a selling point to customers who want to do their own internal inventory tracking. Devicemakers aren’t required to comply before the FDA deadlines, but may want to so as a customer-service step, he suggested.

Once UDI is imposed, expect FDA investigators to put it to work, Niedelman told conference-goers. “The FDA will use UDI labels to segue into design changes, design controls and labeling controls,” he said. “They’ll use it as a tool to drive through your quality system.”

Another concern to keep on the radar screen is verifying the bar codes used in UDIs, Crowley said. Companies are frequently lax about double checking bar codes for commercial use, but it becomes essential to ensure their readability when UDI is a factor, he added.

The Sept. 24 UDI deadline is right around the corner. Make sure you’re fully prepared by purchasing The FDAnews UDI Compliance Kit.

Medical Devices Regulatory Affairs

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing